Can-Fite BioPharma provided an update on its Phase II clinical trial of drug candidate Namodenoson, or CF102, for the treatment of advanced hepatocellular carcinoma, or HCC, in patients whose disease has progressed on sorafenib therapy. Top line efficacy results are expected by end of year. The global Phase II study is being conducted in the U.S., Europe and Israel.
https://thefly.com/landingPageNews.php?id=2785007
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.